Ƶ

More Positive Imcivree Data; ICER Reviews Tirzepatide; SGLT2 Inhibitors for Syncope?

— News and commentary from the endocrinology world

Ƶ MedicalToday
ENDOBREAK centered between 8 illustrated body organs.

Interim data from a (Imcivree) for pediatric and adult patients with Bardet-Biedl Syndrome found an average BMI reduction of 14.3% from baseline and a 14.9% drop in body weight, Rhythm Pharmaceuticals announced.

A new Institute for Clinical and Economic Review (ICER) report said Eli Lilly's highly anticipated was generally on par -- but not particularly any better -- than existing drugs semaglutide (Ozempic) and empagliflozin (Jardiance). (FiercePharma)

Medicaid, Medicare, as well as Affordable Care Act widely differs from state to state, a new report from the Urban Institute found.

Over half of postmenopausal women over 50 experienced , according to a cross-sectional study. (Menopause)

A preprint, pre-peer reviewed study suggested that SGLT2 inhibitors reduced the risk of in patients with type 2 diabetes. (Cardiovascular Diabetology)

said its once-weekly long-acting recombinant human growth hormone injectable somatrogon (Ngenla) for kids with growth hormone deficiency was given the greenlight by the European Commission, after the for approval last month.

A new study found that a in the hospital had obesity. (University of Hawai'i News)

Pregnant women dealing with , including sleep apnea, may hold a higher risk for developing hypertension and metabolic syndrome. (American Journal of Respiratory and Critical Care Medicine)

A new post-marketing safety analysis found that about 10% of patients on for thyroid eye disease experienced a mild-to-moderate hearing-related adverse event -- comparable to what was seen in the open-label extension clinical trials, Horizon Therapeutics announced.

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.